Intra-Cellular Therapies, Inc.
ITCI · NASDAQ
12/31/2024 | 9/30/2024 | 6/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Revenue | $199 | $175 | $161 | $145 |
| % Growth | 13.7% | 8.5% | 11.4% | – |
| Cost of Goods Sold | $20 | $15 | $11 | $10 |
| Gross Profit | $179 | $160 | $150 | $135 |
| % Margin | 89.8% | 91.3% | 93% | 93.2% |
| R&D Expenses | $70 | $67 | $56 | $43 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $138 | $132 | $122 | $113 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | $0 | $0 |
| Operating Expenses | $208 | $199 | $178 | $156 |
| Operating Income | -$29 | -$39 | -$28 | -$21 |
| % Margin | -14.7% | -22.2% | -17.2% | -14.5% |
| Other Income/Exp. Net | $12 | $13 | $12 | $6 |
| Pre-Tax Income | -$17 | -$26 | -$16 | -$15 |
| Tax Expense | -$0 | $0 | $0 | $0 |
| Net Income | -$17 | -$26 | -$16 | -$15 |
| % Margin | -8.5% | -15% | -10.1% | -10.5% |
| EPS | 0.56 | -0.25 | -0.16 | -0.16 |
| % Growth | 324% | -56.3% | 0% | – |
| EPS Diluted | 0.56 | -0.25 | -0.16 | -0.16 |
| Weighted Avg Shares Out | 103 | 106 | 104 | 97 |
| Weighted Avg Shares Out Dil | 103 | 106 | 104 | 97 |
| Supplemental Information | – | – | – | – |
| Interest Income | $12 | $13 | $12 | $6 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$29 | -$39 | -$28 | -$21 |
| % Margin | -14.6% | -22.1% | -17.1% | -14.4% |